Press Releases

Date Title and Summary Additional Formats
Toggle Summary Seattle Genetics and Takeda Present Positive Data from Phase 3 ECHELON-2 Clinical Trial for ADCETRIS® (Brentuximab Vedotin) in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas
-Data Presented in Oral Session with Simultaneous Publication in The Lancet- -Randomized Phase 3 Clinical Trial Demonstrated ADCETRIS plus Chemotherapy Resulted in Superior Progression-Free Survival and Overall Survival Compared to a Standard of Care, CHOP- BOTHELL, Wash. & CAMBRIDGE, Mass.
View HTML
Toggle Summary Seattle Genetics Highlights Additional Analyses from ECHELON-1 Phase 3 Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Newly Diagnosed Advanced Hodgkin Lymphoma at ASH Annual Meeting
-Data Continue to Show Superior Clinical Activity of ADCETRIS in Combination with AVD when Compared to ABVD in Frontline Advanced Hodgkin Lymphoma- -Three-Year Progression-Free Survival Data Demonstrate ADCETRIS plus AVD Benefit of 83.1 Percent Compared to 76.0 Percent in ABVD Arm- -ADCETRIS in
View HTML
Toggle Summary Seattle Genetics Highlights Multiple Data Sets Evaluating the Combination of ADCETRIS® (Brentuximab Vedotin) and Opdivo® (Nivolumab) at ASH Annual Meeting
-Initial Data Reported from Phase 2 Clinical Trial in Relapsed Primary Mediastinal Large B-Cell Lymphoma- -Results from Phase 1/2 Trial in Relapsed Hodgkin Lymphoma Continue to Support Combination Strategy- -Phase 2 Trial Evaluating Novel Combination Strategies in Children, Adolescents and Young
View HTML
Toggle Summary Seattle Genetics to Webcast Investor and Analyst Event at American Society of Hematology Annual Meeting
BOTHELL, Wash. --(BUSINESS WIRE)--Nov. 26, 2018-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that the company will webcast an investor and analyst event on  Monday, December 3, 2018  during the 60th  American Society of Hematology  (ASH) Annual Meeting in San Diego, Calif. The program
View HTML
Toggle Summary Seattle Genetics Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) in Combination with Chemotherapy for Adults with Previously Untreated Systemic Anaplastic Large Cell Lymphoma or Other CD30-Expressing Peripheral T-Cell Lymphomas
-First FDA-Approved Regimen in Frontline Peripheral T-Cell Lymphoma- -FDA Approval Based on Results from the Phase 3 ECHELON-2 Clinical Trial; Data to be Presented at the 2018 ASH Annual Meeting- -Application Approved Less Than Two Weeks After Submission Under FDA Real-Time Oncology Review Pilot
View HTML
Toggle Summary FDA Grants Breakthrough Therapy Designation to ADCETRIS® (Brentuximab Vedotin) for Frontline Peripheral T-Cell Lymphomas
-Designation Based on Positive Phase 3 ECHELON-2 Trial Evaluating ADCETRIS in Frontline CD30-Expressing Peripheral T-Cell Lymphomas; Data to be Presented at Upcoming American Society of Hematology Annual Meeting in December- BOTHELL, Wash. --(BUSINESS WIRE)--Nov. 15, 2018-- Seattle Genetics, Inc.
View HTML
Toggle Summary Seattle Genetics Initiates Phase 1 Clinical Trial of SEA-BCMA for Patients with Relapsed or Refractory Multiple Myeloma
-SEA-BCMA is a Novel Empowered Antibody Targeting BCMA for Multiple Myeloma- -Adds to Seattle Genetics’ Robust Clinical-Stage Development Pipeline across Multiple Hematologic and Solid Tumors- BOTHELL, Wash. --(BUSINESS WIRE)--Nov. 14, 2018-- Seattle Genetics, Inc.
View HTML
Toggle Summary Seattle Genetics to Present at the Credit Suisse 27th Annual Healthcare Conference
BOTHELL, Wash. --(BUSINESS WIRE)--Nov. 6, 2018-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Credit Suisse 27 th Annual Healthcare Conference on Tuesday, November 13, 2018 at 2:15 p.m. Mountain Time . The presentation will be webcast live and available
View HTML
Toggle Summary Seattle Genetics Submits Supplemental Biologics License Application for ADCETRIS® (Brentuximab Vedotin) in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas
-Submission Based on Positive Phase 3 ECHELON-2 Trial Evaluating ADCETRIS in Frontline CD30-Expressing Peripheral T-Cell Lymphoma- -ECHELON-2 Data will be Presented at Upcoming American Society of Hematology Annual Meeting in December- BOTHELL, Wash. --(BUSINESS WIRE)--Nov.
View HTML
Toggle Summary Seattle Genetics Announces More Than 30 Presentations at ASH 2018 Highlighting Progress with Broad ADCETRIS® (Brentuximab Vedotin) Development Program
-Positive Phase 3 ECHELON-2 Clinical Trial Results to be Presented in Oral Session on Monday, December 3 rd - BOTHELL, Wash. --(BUSINESS WIRE)--Nov. 1, 2018-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that 31 abstracts featuring data from the broad ADCETRIS (brentuximab vedotin)
View HTML
Toggle Summary Seattle Genetics Announces Multiple Data Presentations Evaluating ADCETRIS® (Brentuximab Vedotin) in Patients with Hodgkin Lymphoma at ISHL 2018
-Encore and Additional Analyses from Phase 3 ECHELON-1 Trial Evaluating ADCETRIS in Combination with Chemotherapy in Frontline Advanced HL- -Interim Results from Ongoing Studies of ADCETRIS plus Opdivo ® (Nivolumab) in Frontline or Relapsed Hodgkin Lymphoma- -Five-Year Results from Phase 3 AETHERA
View HTML
Toggle Summary Seattle Genetics Reports Third Quarter 2018 Financial Results
-ADCETRIS ® (Brentuximab Vedotin) Net Sales in U.S. and Canada of $127.0 Million in the Third Quarter- -Positive Top-line Data from ADCETRIS Phase 3 ECHELON-2 Trial in Frontline PTCL; Supplemental BLA Planned for November 2018 ; Full Data to be Presented at ASH Annual Meeting- -Top-line Data from
View HTML
Toggle Summary Genmab and Seattle Genetics Announce Tisotumab Vedotin Data to Be Presented at ESMO 2018 Congress
Data presented from updated analysis of full innovaTV 201 expansion cohort in recurrent or metastatic cervical cancer COPENHAGEN, Denmark & BOTHELL, Wash. --(BUSINESS WIRE)--Oct. 8, 2018-- Genmab A/S (Nasdaq Copenhagen: GEN) and Seattle Genetics, Inc.
View HTML
Toggle Summary Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter Financial Results on October 25, 2018
BOTHELL, Wash. --(BUSINESS WIRE)--Oct. 3, 2018-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its third quarter financial results on Thursday, October 25, 2018 after the close of financial markets. Following the announcement, company management will host a conference
View HTML
Toggle Summary Seattle Genetics and Takeda Announce Positive Results from Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline CD30-Expressing Peripheral T-Cell Lymphoma
-ADCETRIS in Combination with Chemotherapy Achieved Primary Endpoint, Demonstrating a Statistically Significant Improvement in Progression-Free Survival Compared to a Standard of Care Chemotherapy- -Statistically Significant Improvement Achieved in All Key Secondary Endpoints, Including Overall
View HTML
Toggle Summary Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Approval in Japan for Frontline Hodgkin Lymphoma
-Approval Triggers Milestone Payment to Seattle Genetics of $10 Million - BOTHELL, Wash. --(BUSINESS WIRE)--Sep. 21, 2018-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that its collaborator, Takeda Pharmaceutical Company Limited (Takeda), has received approval from the Japanese Ministry
View HTML
Toggle Summary Seattle Genetics to Present at the Morgan Stanley Global Healthcare Conference
BOTHELL, Wash. --(BUSINESS WIRE)--Sep. 4, 2018-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Morgan Stanley Global Healthcare Conference on Thursday, September 13, 2018 at 2:05 p.m. EDT . The presentation will be webcast live and available for replay
View HTML
Toggle Summary Seattle Genetics Reports Second Quarter 2018 Financial Results
-Record ADCETRIS ®  (Brentuximab Vedotin) Net Sales in U.S. and Canada of $122.4 Million in the Second Quarter- -ADCETRIS ECHELON-2 Top-line Results Expected in Early Fourth Quarter 2018- -Enrollment Completed in Pivotal Trial Cohort of Enfortumab Vedotin in Metastatic Urothelial Cancer; EV
View HTML
Toggle Summary Seattle Genetics Announces First Patient Dosed in Phase 2 innovaTV 207 Trial Evaluating Tisotumab Vedotin in Multiple Solid Tumors
-Trial to Inform Broader Development Program Strategy- -Trial is Enrolling Patients with Colorectal, Non-Small Cell Lung, Pancreatic or Head and Neck Cancers- BOTHELL, Wash. --(BUSINESS WIRE)--Jul. 12, 2018-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced dosing of the first patient in the
View HTML
Toggle Summary Seattle Genetics Announces Publication of Results from Two Tucatinib Phase 1b Clinical Trials in HER2-Positive Metastatic Breast Cancer
Results of Combination “Triplet” of Tucatinib with Trastuzumab and Capecitabine Published in The Lancet Oncology Results of Tucatinib in Combination with Ado-trastuzumab Emtansine Published in JAMA Oncology BOTHELL, Wash. --(BUSINESS WIRE)--Jul. 11, 2018-- Seattle Genetics, Inc.
View HTML
Toggle Summary Seattle Genetics and Astellas Announce Progress in Enfortumab Vedotin Urothelial Cancer Clinical Development Program
-Enrollment of EV-201 Pivotal Trial Cohort Designed to Support Potential Expedited Registration Pathway in the U.S. Completed- -First Patient Dosed in Phase 3 Global Confirmatory Trial- BOTHELL, Wash. & TOKYO --(BUSINESS WIRE)--Jul. 9, 2018-- Seattle Genetics, Inc.
View HTML
Toggle Summary Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter Financial Results on July 26, 2018
BOTHELL, Wash. --(BUSINESS WIRE)--Jun. 28, 2018-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its second quarter financial results on Thursday, July 26, 2018 after the close of financial markets. Following the announcement, company management will host a conference
View HTML
Toggle Summary Seattle Genetics Announces First Patient Dosed in Phase 2 Trial of Tisotumab Vedotin for Women with Recurrent or Metastatic Cervical Cancer
-Tisotumab Vedotin to be Evaluated as a Monotherapy in Patients Who Have Relapsed or Progressed After Standard of Care Treatment- -Tisotumab Vedotin Represents Fourth Late-Stage Development Program Added to List of Ongoing Pivotal Trials Along with Enfortumab Vedotin and Tucatinib- BOTHELL, Wash.
View HTML
Toggle Summary Seattle Genetics to Present at the Goldman Sachs 39th Annual Global Healthcare Conference
BOTHELL, Wash. --(BUSINESS WIRE)--Jun. 6, 2018-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Goldman Sachs 39 th Annual Global Healthcare Conference on Wednesday, June 13, 2018 at 1:20 p.m. Pacific Time . The presentation will be webcast live and
View HTML
Toggle Summary Seattle Genetics Highlights Additional Analyses from Phase 3 ECHELON-1 Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Newly Diagnosed Advanced Hodgkin Lymphoma at 2018 ASCO Annual Meeting
Data Continue to Support Superior Clinical Activity of ADCETRIS in Combination with Chemotherapy when Compared to ABVD in Frontline Advanced Hodgkin Lymphoma Results from Patients Treated in North America Demonstrate Two-Year Modified Progression-Free Survival of 84.3 Percent in the ADCETRIS
View HTML
Toggle Summary Seattle Genetics and Astellas Present at ASCO 2018 on Enfortumab Vedotin in Patients with Locally Advanced or Metastatic Urothelial Cancer Previously Treated with Checkpoint Inhibitor Therapy
-Updated Data from Phase 1 EV-101 Study Highlighted in ASCO 2018 Oral Presentation Support Rapid Development Program and Ongoing Pivotal Study- BOTHELL, Wash. & TOKYO --(BUSINESS WIRE)--Jun. 3, 2018-- Seattle Genetics, Inc. (Nasdaq: SGEN) and Astellas Pharma Inc.
View HTML
Toggle Summary Seattle Genetics Appoints Roger D. Dansey, M.D., Chief Medical Officer
BOTHELL, Wash. --(BUSINESS WIRE)--May 17, 2018-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced the appointment of Roger D. Dansey , M.D., as Chief Medical Officer. Dr. Dansey brings extensive experience in cancer drug development, most recently from Merck Inc.
View HTML
Toggle Summary Seattle Genetics Announces Data Presentations at 2018 ASCO Annual Meeting
BOTHELL, Wash. --(BUSINESS WIRE)--May 17, 2018-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that multiple abstracts from its robust clinical development portfolio will be presented at the upcoming 2018 American Society of Clinical Oncology ( ASCO ) Annual Meeting in Chicago, Illinois ,
View HTML
Toggle Summary Seattle Genetics to Present at the Bank of America Merrill Lynch Health Care Conference 2018
BOTHELL, Wash. --(BUSINESS WIRE)--May 2, 2018-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Bank of America Merrill Lynch Health Care Conference 2018 on Tuesday, May 15, 2018 at 5:00 p.m. Pacific Time . The presentation will be webcast live and available
View HTML
Toggle Summary Seattle Genetics Reports First Quarter 2018 Financial Results
-Record ADCETRIS ® (Brentuximab Vedotin) Net Sales in U.S. and Canada of $95.4 Million in the First Quarter- -ADCETRIS Approved by FDA in Frontline Stage III/IV Classical Hodgkin Lymphoma- -ECHELON-2 Data Expected in 2018- -Conference Call Today at 4:30 p.m. ET - BOTHELL, Wash.
View HTML
Toggle Summary Seattle Genetics Highlights Novel Antibody-Drug Conjugate Technologies and Immuno-Oncology Program Advances at the American Association for Cancer Research (AACR) Annual Meeting
BOTHELL, Wash. --(BUSINESS WIRE)--Apr. 12, 2018-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced data highlights from nine presentations showcasing the company’s innovative, proprietary antibody-drug conjugate (ADC) platform technologies as well as its emerging immuno-oncology pipeline.
View HTML
Toggle Summary Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter Financial Results on April 26, 2018
BOTHELL, Wash. --(BUSINESS WIRE)--Apr. 5, 2018-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its first quarter financial results on Thursday, April 26, 2018 after the close of financial markets. Following the results announcement, company management will host a
View HTML
Toggle Summary Seattle Genetics and Astellas Receive FDA Breakthrough Therapy Designation for Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
BOTHELL, Wash. & TOKYO --(BUSINESS WIRE)--Mar. 26, 2018-- Seattle Genetics, Inc. (NASDAQ: SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka , “Astellas”) today announced that the U.S. Food and Drug Administration ( FDA ) has granted Breakthrough Therapy Designation to
View HTML
Toggle Summary Seattle Genetics Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) in Combination with Chemotherapy for Adults with Previously Untreated Stage III or IV Classical Hodgkin Lymphoma
First FDA-Approved Regimen in Frontline Stage III or IV Classical Hodgkin Lymphoma in More Than 40 Years FDA Approval Based on Clinical Trial Results from the Phase 3 ECHELON-1 Clinical Trial Label Expansion Represents Fifth Indication for ADCETRIS in the U.S.; ECHELON-1 Trial Also Converts Prior
View HTML
Toggle Summary Seattle Genetics Appoints Dr. Alpna Seth to Board of Directors
BOTHELL, Wash. --(BUSINESS WIRE)--Mar. 15, 2018-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that Alpna Seth , Ph.D. has been appointed to the company’s Board of Directors. Dr. Seth has more than 20 years of global experience in the healthcare and biotechnology/pharmaceutical industry,
View HTML
Toggle Summary Seattle Genetics to Present at the Barclays Global Healthcare Conference 2018
BOTHELL, Wash. --(BUSINESS WIRE)--Mar. 13, 2018-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Barclays Global Healthcare Conference 2018 on Wednesday, March 14, 2018 at 10:45 a.m. Eastern Time . The presentation will be webcast live and available for
View HTML
Toggle Summary Seattle Genetics Completes Acquisition of Cascadian Therapeutics
-Transaction Provides Global Rights to Tucatinib, a Potentially Best-in-Class Tyrosine Kinase Inhibitor for HER2-Positive Metastatic Breast Cancer- -Ongoing Pivotal Trial HER2CLIMB Expected to Complete Enrollment in 2019- BOTHELL, Wash. --(BUSINESS WIRE)--Mar. 9, 2018-- Seattle Genetics, Inc.
View HTML
Toggle Summary Seattle Genetics Completes Tender Offer for All Shares of Cascadian Therapeutics
BOTHELL, Wash. --(BUSINESS WIRE)--Mar. 9, 2018-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced the expiration of the tender offer (the “Offer”) by a wholly owned subsidiary, “Merger Sub”, for all of the shares of common stock of Cascadian Therapeutics, Inc.
View HTML
Toggle Summary Seattle Genetics Initiates New Phase 1 Study in Relapsed or Refractory Multiple Myeloma
Antibody-Drug Conjugate (ADC) SGN-CD48A Being Evaluated as Monotherapy, With Innovative Linker Technology That Highlights Continued Industry Leadership in ADCs BOTHELL, Wash. --(BUSINESS WIRE)--Mar. 7, 2018-- Seattle Genetics, Inc. (NASDAQ: SGEN) today announced dosing of the first patient in a
View HTML
Toggle Summary Seattle Genetics to Present at Cowen and Company 38th Annual Health Care Conference
BOTHELL, Wash. --(BUSINESS WIRE)--Feb. 27, 2018-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Cowen and Company 38th Annual Health Care Conference on Tuesday, March 13, 2018 at 9:20 a.m. Eastern Time . The presentation will be webcast live and available
View HTML
Toggle Summary Seattle Genetics Announces Expiration of Hart-Scott-Rodino Waiting Period
BOTHELL, Wash. --(BUSINESS WIRE)--Feb. 16, 2018-- Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the “HSR Act”) with respect to Seattle Genetics’ proposed acquisition of Cascadian Therapeutics,
View HTML
Toggle Summary Seattle Genetics and Pieris Pharmaceuticals Announce Multi-Program Immuno-Oncology Collaboration
-Companies to Evaluate Novel Bispecific Immuno-Oncology Agents that Combine Pieris’ Anticalin Technology with Select Seattle Genetics Cancer-Targeted Antibodies- BOSTON & BOTHELL, Wash. --(BUSINESS WIRE)--Feb. 9, 2018-- Pieris Pharmaceuticals , Inc. (NASDAQ: PIRS), a clinical-stage biotechnology
View HTML
Toggle Summary Seattle Genetics Commences Tender Offer for Cascadian Therapeutics, Inc.
BOTHELL, Wash. --(BUSINESS WIRE)--Feb. 8, 2018-- Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that its wholly-owned subsidiary, Valley Acquisition Sub, Inc. , has commenced its previously announced tender offer for all outstanding shares of common stock of Cascadian Therapeutics, Inc.
View HTML
Toggle Summary Seattle Genetics Reports Fourth Quarter and Year 2017 Financial Results
-Record ADCETRIS ® (Brentuximab Vedotin) Net Sales in U.S. and Canada of $307.6 Million in 2017, Including $83.7 Million in the Fourth Quarter- -ECHELON-1 Supplemental BLA for ADCETRIS in Combination with Chemotherapy for Frontline Advanced Classical Hodgkin Lymphoma Granted FDA Priority Review and
View HTML
Toggle Summary Seattle Genetics Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
BOTHELL, Wash. --(BUSINESS WIRE)--Feb. 2, 2018-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that the underwriters of its previously announced underwritten public offering have exercised in full their option to purchase an additional 1,730,769 shares of Seattle Genetics’ common stock.
View HTML
Toggle Summary Seattle Genetics Announces Pricing of Public Offering of Common Stock
BOTHELL, Wash. --(BUSINESS WIRE)--Feb. 1, 2018-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced the pricing of an underwritten public offering of 11,538,461 shares of its common stock at a price to the public of $52.00 per share. All of the shares are being sold by Seattle Genetics .
View HTML
Toggle Summary Seattle Genetics Announces Proposed Public Offering of Common Stock
BOTHELL, Wash. --(BUSINESS WIRE)--Jan. 31, 2018-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that it has commenced an underwritten public offering of $550.0 million of shares of its common stock. All of the shares are being offered by Seattle Genetics .
View HTML
Toggle Summary Seattle Genetics to Acquire Cascadian Therapeutics, Adding Late-Stage Breast Cancer Program to Its Oncology Pipeline
-Enhances Seattle Genetics’ Portfolio of Solid Tumor Programs with Potential Rapid Registrational Pathways- -Provides Global Rights to Pivotal Phase 2 Program in Development for HER2-Positive Metastatic Breast Cancer- -Conference Call Today at 8:30 a.m. ET - BOTHELL, Wash.
View HTML
Toggle Summary Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Receives European Commission Approval for CD30-Positive Cutaneous T-Cell Lymphoma after at Least One Prior Systemic Therapy
Approval Based on Positive Phase 3 ALCANZA Trial Results, which Demonstrated a Highly Statistically Significant Improvement in Rate of Objective Response Lasting at Least Four Months, Median Progression-Free Survival, and Improvement in Symptom Burden in ADCETRIS Arm BOTHELL, Wash.
View HTML
Toggle Summary Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2017 Financial Results on February 6, 2018
BOTHELL, Wash. --(BUSINESS WIRE)--Jan. 18, 2018-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its fourth quarter and year 2017 financial results on Tuesday, February 6, 2018 after the close of financial markets. Following the results announcement, company management
View HTML
Toggle Summary Seattle Genetics Highlights Leadership in Expanding Field of Antibody-Drug Conjugates (ADCs) at the 36th Annual J.P. Morgan Healthcare Conference
-Continued Progress In Establishing ADCETRIS® (brentuximab vedotin) as the Foundation of Care for CD30-Expressing Lymphomas - -Two Solid Tumor ADC Programs Advancing Under Accelerated Approval Pathways- -Multiple Collaborator ADC Programs in Late-Stage Trials for Range of Tumor Types- BOTHELL,
View HTML
Toggle Summary FDA Accepts Supplemental Biologics License Application and Grants Priority Review for ADCETRIS® (Brentuximab Vedotin) in Frontline Advanced Hodgkin Lymphoma
-PDUFA Action Date May 1, 2018 - -Submission Based on Positive Results from the Phase 3 ECHELON-1 Clinical Trial- -FDA Previously Granted Breakthrough Therapy Designation for ADCETRIS in Frontline Advanced Hodgkin Lymphoma- BOTHELL, Wash. --(BUSINESS WIRE)--Jan. 2, 2018-- Seattle Genetics, Inc.
View HTML